Persistent Dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the dyslipidemia international study (DYSIS)

Wiener Klinische Wochenschrift

Volumn 123, Issue 19-20, 2011, Pages 611-617

  Drexel, Heinz ^a,b   Chazelle, Francois ^c   Fauer, Christiane ^d   Lautsch, Dominik ^b,d   Gitt, Anselm K ^e  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^c MSD France   (France)

^d MSD Austria   (Austria)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

HDL cholesterol; LDL cholesterol; Lipids; Primary prevention; Secondary prevention; Statins; Triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOLOGIST; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; DYSLIPIDEMIA; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; AUSTRIA; CHRONIC DISEASE; COMORBIDITY; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PREVALENCE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 83855164103     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-011-0057-1     Document Type: Article

References (15)

1. British Heart Foundation. European cardiovascular disease statistics. British Heart Foundation, London 2005
2. WP Castelli 1988 Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study Can J Cardiol 4 5A 10A 3179802
3. JH O'Keefe Jr L Cordain WH Harris RM Moe R Vogel 2004 Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal J Am Coll Cardiol 43 2142 2146 15172426 10.1016/j.jacc.2004.03.046 (Pubitemid 38686815)
4. C Baigent A Keech PM Kearney L Blackwell G Buck C Pollicino A Kirby T Sourjina R Peto R Collins R Simes Cholesterol Treatment Trialists' (CTT) Collaborators 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267 1278 16214597 10.1016/S0140-6736(05)67394-1 1:CAS:528:DC%2BD2MXhtVOlu7fM (Pubitemid 41416582)
5. Cholesterol Treatment Trialists' (CTT) Collaborators PM Kearney L Blackwell R Collins A Keech J Simes R Peto J Armitage C Baigent 2008 Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 117 125 18191683 10.1016/S0140-6736(08)60761-8 1:STN:280:DC%2BD1c%2FjvVWmsg%3D%3D (Pubitemid 351697949)
6. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice 2007 European guidelines on cardiovascular disease prevention in clinical practice: Executive summary Eur Heart J 28 2375 2414 10.1093/eurheartj/ehm316 (Pubitemid 47542237)
7. PK Shah S Kaul J Nilsson B Cercek 2001 Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming, part I Circulation 104 2376 2383 11696481 10.1161/hc4401.098467 1:CAS:528:DC%2BD3MXpt1WltrY%3D (Pubitemid 33049524)
8. AM Gotto Jr 2002 High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease Am Heart J 144 6 Suppl. 33 42 10.1067/mhj.2002.130301 (Pubitemid 36026903)
9. PJ Barter R Puranik KA Rye 2007 New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease Curr Cardiol Rep 9 493 498 17999875 10.1007/BF02938394 (Pubitemid 350081421)
10. K Kotseva D Wood G De Backer D De Bacquer K Pyörälä U Keil EUROASPIRE Study Group 2009 Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries Lancet 373 929 940 19286092 10.1016/S0140-6736(09)60330-5
11. M Roden K Huber für die HSP-Projektgruppe 2008 Lipidprofil und Therapiestatus in der Sekundärprävention bei Hochrisiko-Patienten mit klinisch manifester Arteriosklerose und/oder Diabetes mellitus: Das Hospital Screening Projekt (HSP) in Österreich Wien Klin Wochenschr 120 558 565 18988009 10.1007/s00508-008-1010-9
12. H Drexel S Aczel T Marte A Vonbank CH Saely 2010 Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis Atherosclerosis 208 484 489 19748621 10.1016/j.atherosclerosis.2009.08.026 1:CAS:528:DC%2BC3cXhtlyqsLw%3D
13. Austrian Lipid Consensus. Management of lipid disorders fort he prevention of vascular complications. Joint consensus statement of eight Austrian medical societies 2010
14. JC LaRosa SM Grundy DD Waters, et al. 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 1425 1435 15755765 10.1056/NEJMoa050461 1:CAS:528:DC%2BD2MXjtVWltrw%3D (Pubitemid 40471450)
15. AJ Taylor TC Villines EJ Stanek, et al. 2009 Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2113 2122 19915217 10.1056/NEJMoa0907569 1:CAS:528:DC%2BD1MXhsFSnsLzP